# INO-3107 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ino-3107

> The PDUFA target action date for INO-3107, sponsored by INOVIO PHARMACEUTICALS, INC. (INO), is Q1 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the INO-3107 PDUFA date?

The PDUFA target action date for INO-3107, sponsored by INOVIO PHARMACEUTICALS, INC. (INO), is Q1 2027. Status: scheduled. Press release filed with the SEC (EX-99): "INOVIO estimates that current cash, cash equivalents and short-term investments balances will support operations into the first quarter of 2027, beyond the target PDUFA date for INO-3107." Last confirmed May 13, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/ino-3107)

Source: Press release filed with the SEC (EX-99), accession 0001055726-26-000019, https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm (retrieved 2026-11-12). Last confirmed 2026-05-13. Cite: https://sec-api.dev/pdufa/ino-3107#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | INO-3107 |
| Codes | INO-3107 |
| Sponsor | INOVIO PHARMACEUTICALS, INC. (INO) https://sec-api.dev/companies/ino/catalysts |
| Indications | rrp and set the prescription drug user fee act, recurrent respiratory papillomatosis |
| Modality |  |
| FDA designations | accelerated, breakthrough, orphan, priority review |

## Timeline

### 2H 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2024-11-14, last confirmed 2025-08-12.
- Press release filed with the SEC (EX-99) (accession 0001055726-25-000056): "•On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end" https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/ino-63025x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-25-000027): "•On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025" https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-33125x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-25-000027): "◦Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25" https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-33125x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-25-000027): "INOVIO plans to begin rolling submission of the BLA in mid-2025 under FDA's accelerated approval program, subject to FDA concurrence, with the goal of completing the submission in the second half of 2025 and receiving FDA acceptance of the submission by the end of the year." https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-33125x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-24-000053): "With this progress, we continue to target the submission of our BLA in mid-2025," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer." https://www.sec.gov/Archives/edgar/data/1055726/000105572624000053/ino-93024x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-24-000053): "Recent progress includes advancing preparations for submitting the BLA, targeted for mid-2025, and announcing the following new data." https://www.sec.gov/Archives/edgar/data/1055726/000105572624000053/ino-93024x8kex991.htm

### Jul 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-11-10, last confirmed 2025-11-10.
- SEC Form 10-Q (accession 0001055726-25-000063): "In addition, we have several series of warrants outstanding that may be exercised at any time; for example, as of the date hereof, we have outstanding Series A warrants to purchase up to 13,857,144 shares of common stock in July 2025, which will expire on the date that is the earlier of (i) 12 months from the date of issuance or (ii) 30 days after the date on which we first publicly disclose, whether by press release or Form 8-K filing, the FDA's acceptance of a BLA for INO-3107." https://www.sec.gov/Archives/edgar/data/1055726/000105572625000063/ino-20250930.htm

### Nov 2025: NDA/BLA acceptance

- Status: scheduled. Date confidence: month.
- First seen 2025-11-10, last confirmed 2025-11-10.
- SEC Form 10-Q (accession 0001055726-25-000063): "We requested rolling submission of our BLA for INO-3107 in July 2025 and reported in November 2025 that we had completed the BLA submission, with the goal of receiving file acceptance by the FDA by the end of 2025." https://www.sec.gov/Archives/edgar/data/1055726/000105572625000063/ino-20250930.htm

### Nov 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-03-12, last confirmed 2026-03-12.
- SEC Form 10-K (accession 0001055726-26-000008): "In November 2025, we announced that we had submitted our BLA for INO-3107 as a treatment for adults with RRP under the FDA's accelerated approval program." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm

### December 29, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: RRP and set the Prescription Drug User Fee Act.
- First seen 2025-12-29, last confirmed 2026-08-12.
- SEC Form 8-K (accession 0001193125-25-332322): "As described in Item 8.01 below, on December 29, 2025, Inovio Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted the Company's Biologic License Application ("BLA") for INO-3107, an investigational immunotherapy for the treatment of recurrent respiratory papillomatosis ("RRP") in adults." https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035d8k.htm
- SEC Form 8-K (accession 0001193125-25-332322): "On December 29, 2025, the Company announced that the FDA has accepted the Company's BLA for INO-3107 for review as a potential treatment for adults with RRP." https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-332322): "PLYMOUTH MEETING, PA., December 29, 2025 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for INO-3107 for review as a potential treatment for adults with RRP." https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000019): "In December 2025, the FDA accepted for review the company's BLA for INO-3107 under the accelerated approval program and set a target PDUFA date for October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000009): "In December 2025, the FDA accepted INOVIO's BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/ino-123125x8kex991.htm
- SEC Form 10-Q (accession 0001055726-26-000023): "In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act (PDUFA) target date for October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000023/ino-20260630.htm
- SEC prospectus (424B) (accession 0001193125-26-326370): "In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act, or PDUFA, target date for October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000119312526326370/d155272d424b5.htm
- SEC Form 10-Q (accession 0001055726-26-000018): "In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act (PDUFA) target date for October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000018/ino-20260331.htm

### February 6, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2026-07-30, last confirmed 2026-07-30.
- SEC prospectus (424B) (accession 0001193125-26-326370): "For example, a purported shareholder class action complaint was filed against us on February 6, 2026 and three purported shareholder derivative complaints have been filed against us on March 5, 2026, March 16, 2026 and July 23, 2026, naming us and our executive officers as defendants, and alleging that we made materially false and misleading statements regarding the submission to the FDA and the FDA's review timeline for our BLA for INO-3107 in violation of certain federal securities laws." https://www.sec.gov/Archives/edgar/data/1055726/000119312526326370/d155272d424b5.htm

### mid-2026: PDUFA date

- Status: delayed. Date confidence: half.
- First seen 2025-05-13, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0001055726-25-000027): "FDA has previously awarded breakthrough therapy designation for INO-3107 and INOVIO plans to request priority review of its BLA, which if granted would allow for an FDA approval decision (PDUFA date) in mid-2026." https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-33125x8kex991.htm

### October 30, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-11-05, last confirmed 2026-11-06.
- SEC prospectus (424B) (accession 0001193125-26-451932): " the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026, and the yet-to-be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program;" https://www.sec.gov/Archives/edgar/data/1055726/000119312526451932/d141720d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-449837): " the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026, and the yet-to-be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program;" https://www.sec.gov/Archives/edgar/data/1055726/000119312526449837/d141720d424b5.htm

### October 30, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-12-29, last confirmed 2026-11-06.
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000024): "The FDA's review of the BLA for INO-3107 continues to advance under the Agency's accelerated approval program toward a PDUFA target action date of October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000024): "the FDA's continued review of our BLA for INO-3107 toward a PDUFA target action date of October 30, 2026" https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000019): "•Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026" https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000019): "In December 2025, the FDA accepted for review the company's BLA for INO-3107 under the accelerated approval program and set a target PDUFA date for October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000019): "the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026" https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000009): ""Our top priority is advancing INO-3107, and to do so, optimizing and extending our financial resources towards our target PDUFA date of October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/ino-123125x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000009): "the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026" https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/ino-123125x8kex991.htm
- SEC Form 8-K (accession 0001193125-25-332322): "The FDA assigned INO-3107 a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, which is the date by which it intends to take action on the application." https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-332322): "PDUFA target action date set for October 30, 2026, the FDA's plans not to hold an advisory committee meeting to discuss the application, INOVIO's ability to access the accelerated approval pathway, as well as the potential benefits of INO-3107." https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035dex991.htm
- SEC prospectus (424B) (accession 0001193125-26-451932): "INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act, or PDUFA, target date for October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000119312526451932/d141720d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-451932): " the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026, and the yet-to-be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program;" https://www.sec.gov/Archives/edgar/data/1055726/000119312526451932/d141720d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-449837): "INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act, or PDUFA, target date for October 30, 2026." https://www.sec.gov/Archives/edgar/data/1055726/000119312526449837/d141720d424b5.htm

### Q1 2027: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2026-05-13, last confirmed 2026-05-13.
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000019): "INOVIO estimates that current cash, cash equivalents and short-term investments balances will support operations into the first quarter of 2027, beyond the target PDUFA date for INO-3107." https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001055726-26-000019): "•Current cash, cash equivalents, and short-term investments anticipated to fund operations into first quarter 2027, beyond the target PDUFA date" https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ino-3107.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INO-3107 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ino-3107

```bibtex
@misc{secapidev_pdufa_ino_3107_20261116,
  title        = {INO-3107 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ino-3107}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ino_3107_20261116","title":"INO-3107 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ino-3107","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
